Skip to main content
Premium Trial:

Request an Annual Quote

Nabsys Raises $21M in Round Led by Hitachi High-Technologies

NEW YORK – Electronic genome mapping company Nabsys said today that it has raised $21 million in an equity financing round that was led by Hitachi High-Technologies.

Other investors in the round were not disclosed.

The Providence, Rhode Island-based company plans to use the funding to finish developing and commercially launch its HD-Mapping whole-genome electronic mapping platform.

The platform will have applications in research, including de novo genome assembly, structural variant analysis, metagenomics, and microbial strain identification, as well as in cytogenetics.

"This investment round will help Nabsys fulfill its mission to make the analysis of large- and intermediate-scale genomic variation as routine, accurate, and cost effective as the analysis of single-nucleotide variation," said Nabsys Founder and CEO Barrett Bready in a statement.

Tsuyoshi Ogino, general manager of the Innovation Division at Hitachi High-Technologies, said in a statement that there is a strong need for accurate, robust, and scalable genome structural analysis and that the Nabsys HD-Mapping platform "effectively supports this need."

"The company is also a strong fit with our strategy for continued advanced R&D with strategic investments in life sciences," he said.

Last year, Hitachi High-Technologies participated in the Series B funding round of cancer molecular profiling firm OmniSeq, a subsidiary of the Roswell Park Comprehensive Cancer Center.

Nabsys had previously planned to launch its electronic genome mapping platform in 2018, following early-access collaborations, including with a group at the US Centers for Disease Control and Prevention, but hasn't commercialized it yet.

The Brown University spinout underwent a financial restructuring in 2016 after briefly closing its doors. Between 2009 and 2013, Nabsys had raised $41 million in private equity.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.